FEMY — Femasys Inc
NASDAQ · Healthcare · Medical Instruments & Supplies
$3.32
+$0.06 (+1.84%)
Femasys Inc (FEMY) is a medical instruments & supplies company listed on NASDAQ. It is led by Kathy Lee-Sepsick M.B.A., based in 3950 Johns Creek Court, Suwanee, GA, United States, 30024, with about 51 employees. Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. It also provides FemBloc, a non-surgical female permanent birth control solution. The company offers its products to gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
Latest reported FEMY revenue for 2025-09-30 was $729.4K. Net income was -$4.2M. Revenue was up 78.2% from 2025-06-30 to 2025-09-30. FEMY currently screens at market cap $925.2K.
Use this FEMY page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the FEMY quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the FEMY SEC filings page. Lician reads the product cache first so this HTML stays unique to Femasys Inc even when a live quote feed is slow.
About Femasys Inc
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. It also provides FemBloc, a non-surgical female permanent birth control solution. The company offers its products to gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
FEMY Key Statistics
Market Cap
$0.93M
Volume
166,470
Previous Close
$2.98
Day Range
$2.81 – $3.06
EPS
-$0.85
Revenue
$1.63M
Net Income
-$18.82M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+52.0%
Profit Margin
-1155.0%
Employees
51
FEMY Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $1.63M | $1.07M | $1.21M | $1.18M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$18.82M | -$14.25M | -$11.39M | -$7.54M |
| EPS (Diluted) | -$0.85 | -$0.93 | -$0.96 | -$1.12 |
Total Assets
$12.45M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$3.45M
Operating Cash Flow
-$19.44M
Free Cash Flow
$0.00
Femasys Inc Company Information
- Founder, President, CEO & Director
- Kathy Lee-Sepsick M.B.A.
- Headquarters
- 3950 Johns Creek Court, Suwanee, GA, United States, 30024
- Website
- femasys.com
- Phone
- 770 500 3910
- IPO / Founded
- 2021-06-18
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies